|
**Overview**: Blood Urea Nitrogen Panel**Introduction**: The Blood Urea Nitrogen Panel is a diagnostic tool designed to assess kidney function using serum samples. In India, chronic kidney disease (CKD) affects ~17 percent of adults (high in diabetes/hypertension patients), with elevated BUN indicating pre-renal, renal, or post-renal impairment. Urea measurement complements creatinine for GFR estimation. High morbidity from underdiagnosis in rural/low-SES populations, limited nephrology access, delayed management leading to end-stage renal disease or dialysis need. Per biochemistry practices aligned with ICMR and Indian Society of Nephrology guidelines, the test employs spectrophotometry for BUN and urea analysis over 1-2 days with high sensitivity/specificity, valuable for initial kidney evaluation. This diagnostic falls under kidney function screening and targets patients with suspected renal impairment, addressing accurate detection to guide hydration, diet, or referral. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing progression. Its serum-based approach ensures reliable detection.**Other Names**: BUN Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Standard renal function test; in India, widely used in diabetes screening.**Purpose**: The test assesses 2 parameters including blood urea nitrogen to guide kidney function evaluation, detect impairment, inform management.**Test Parameters**: 1. Blood Urea Nitrogen, 2. Urea.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report fatigue, edema, oliguria, or risk factors (diabetes, hypertension).**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on urine output, swelling, diabetes, hypertension, medication use.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated kidney impairment including dialysis need, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or dehydration can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated BUN indicates kidney impairment, necessitating specialist input. Normal may require follow-up in high-risk individuals.**Specialist Consultation**: Nephrologists should be consulted for management.**Additional Supporting Tests**: Creatinine, eGFR, urine analysis for confirmation.**Test Limitations**: BUN may be influenced by diet/protein intake; comprehensive approach required.**References**: Indian Journal of Nephrology 2024, CKD Studies India 2023. |
